We are live on
!
Find out more
ACM
ACT Capital Management Portfolio holdings
AUM
$153M
This Fund
S&P 500
This Quarter
Est. Return
-15.2%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$138M
AUM Growth
-$54.6M
(-28%)
Cap. Flow
-$14.6M
Cap. Flow
% of AUM
-10.54%
Top 10 Holdings %
Top 10 Hldgs %
60.84%
Holding
122
New
13
Increased
15
Reduced
28
Closed
30
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$2.49M |
| 2 |
Adtran
ADTN
|
+$2.33M |
| 3 |
Vir Biotechnology
VIR
|
+$2.27M |
| 4 |
Stratasys
SSYS
|
+$1.84M |
| 5 |
PubMatic
PUBM
|
+$1.47M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TRIL
Trillium Therapeutics Inc.
TRIL
|
+$8.18M |
| 2 |
Affirm
AFRM
|
+$2.92M |
| 3 |
Upstart Holdings
UPST
|
+$2.87M |
| 4 |
NUAN
Nuance Communications, Inc.
NUAN
|
+$2.06M |
| 5 |
Atara Biotherapeutics
ATRA
|
+$1.81M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 81.56% |
| 2 | Technology | 7% |
| 3 | Communication Services | 4.59% |
| 4 | Consumer Discretionary | 2.09% |
| 5 | Energy | 2.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
STAAR Surgical
STAA
$1.04B
| $23.6M | 17.04% |
258,100
-10,100
| -4% | -$1.08M |
|
2
Arcturus Therapeutics
ARCT
$456M
| $17.7M | 12.83% |
479,400
+24,100
| +5% | +$982K |
|
3
Arrowhead Research
ARWR
$9.39B
| $14M | 10.09% |
210,500
+16,500
| +9% | +$1.13M |
|
|
CLSD
4
DELISTED
Clearside Biomedical
CLSD
| $6.83M | 4.94% |
165,567
+1,067
| +0.6% | +$69.1K |
|
5
Aurinia Pharmaceuticals
AUPH
$2.25B
| $4.31M | 3.12% |
188,500
+8,500
| +5% | +$201K |
|
6
Krystal Biotech
KRYS
$9.97B
| $4.13M | 2.98% |
59,000
+19,000
| +48% | +$1.11M |
|
7
IDEAYA Biosciences
IDYA
$3.71B
| $4.1M | 2.97% |
173,500
| – | – |
|
8
FuboTV Inc
FUBO
$303M
| $3.58M | 2.59% |
19,208
-1,934
| -9% | -$544K |
|
9
Natera
NTRA
$53.2B
| $3.03M | 2.19% |
32,400
+6,500
| +25% | +$675K |
|
10
United Therapeutics
UTHR
$21.2B
| $2.92M | 2.11% |
13,500
+3,000
| +29% | +$589K |
|
|
11
Adtran
ADTN
$587M
| $2.63M | 1.9% |
+115,000
| New | +$2.33M |
|
|
12
Meta Platforms (Facebook)
META
$1.7T
| $2.52M | 1.82% |
+7,500
| New | +$2.49M |
|
|
13
Vir Biotechnology
VIR
$1.79B
| $2.43M | 1.76% |
+58,000
| New | +$2.27M |
|
14
INmune Bio
INMB
$64.7M
| $2.35M | 1.7% |
230,500
-44,500
| -16% | -$659K |
|
|
ICAD
15
DELISTED
iCAD Inc
ICAD
| $2.33M | 1.69% |
324,100
+99,600
| +44% | +$888K |
|
|
16
Stratasys
SSYS
$701M
| $2.29M | 1.66% |
93,500
+66,000
| +240% | +$1.84M |
|
|
AWH
17
DELISTED
Aspira Women's Health Inc. Common Stock
AWH
| $1.77M | 1.28% |
66,667
-8,714
| -12% | -$331K |
|
18
AirSculpt Technologies
AIRS
$167M
| $1.75M | 1.26% |
+101,500
| New | +$1.42M |
|
|
NVNO
19
enVVeno Medical
NVNO
$6.23M
| $1.73M | 1.25% |
7,500
| – | – |
|
|
AFMD
20
DELISTED
Affimed
AFMD
| $1.71M | 1.23% |
30,880
+2,750
| +10% | +$170K |
|
21
Inhibikase Therapeutics
IKT
$321M
| $1.58M | 1.14% |
179,417
+11,084
| +7% | +$122K |
|
|
22
PubMatic
PUBM
$799M
| $1.53M | 1.11% |
+45,000
| New | +$1.47M |
|
23
Chevron
CVX
$411B
| $1.47M | 1.06% |
12,500
-3,500
| -22% | -$398K |
|
24
Global E Online
GLBE
$6.39B
| $1.43M | 1.03% |
+22,500
| New | +$1.35M |
|
|
MYOV
25
DELISTED
Myovant Sciences Ltd.
MYOV
| $1.32M | 0.96% |
85,000
| – | – |
|
Similar funds
DFG
PB
FFG
DWM
CSF
MWA
BCM
RWM
ACT Capital Management's Q4 2021 Portfolio in Review
As of Q4 2021, ACT Capital Management held 122 positions worth $138M, down 28% from $193M the previous quarter. Its ten largest holdings account for 61% of the portfolio.
ACT Capital Management withdrew a net $14.6M in Q4 2021, closing 30 positions and reducing 28 holdings. Its most notable exit was Trillium Therapeutics Inc., an estimated $8.18M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 83% a quarter earlier, followed by Technology and Communication Services.
Against the trend, ACT Capital Management opened a new position in Meta Platforms (Facebook) worth $2.52M.
- ACT Capital Management's largest Q4 2021 buy was Meta Platforms (Facebook): 7,500 shares worth $2.52M.
- ACT Capital Management added most to Stratasys in Q4 2021, an estimated $1.84M increase.
- ACT Capital Management's biggest Q4 2021 reduction was Upstart Holdings, cutting an estimated $2.87M.
- ACT Capital Management fully exited Trillium Therapeutics Inc. in Q4 2021, selling an estimated $8.18M.
- ACT Capital Management's ten largest holdings make up 61% of its $138M portfolio in Q4 2021.
- ACT Capital Management opened 13 new positions and closed 30 in Q4 2021.
- ACT Capital Management's portfolio value fell 28% quarter-over-quarter to $138M.
Based on ACT Capital Management's 13F filing for Q4 2021, filed 3 Feb 2022.